Cancer Biomarker Testing Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Cancer Biomarker Testing Market by Type Of Cancer (Cervical cancer, Lung Cancer, Collateral Cancer, Liver Cancer, Prostate Cancer, Breast Cancer, Others) and Application (Drug Discovery and Development, Personalised Medicine, Diagnosis, Others) End-User (Hospitals, Cancer diagnostic Centres, Research Institutes, Others)- Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Global Cancer Biomarker Testing Market was valued at USD 10.42 billion in 2020 and is anticipated to grow at USD 20.59 billion by 2027 recording a CAGR of 12.4% during the forecast period 2021-2027. The cancer biomarker test market is driven by rising prevalence of cancer worldwide. World Health Organization (WHO) stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2012. The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO’s funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market. The global market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2017, Foundation Medicine and Bristol-Myers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient’s response to cancer immunotherapy. Using Foundation Medicine’s foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in patients enrolled in clinical trials for Bristol-Myers Squibb (BMS) cancer drugs. For instance, in October 2016, Arquer Diagnostics Ltd. (Arquer), and University of Sunderland are collaborated to investigate noninvasive specimen preparation techniques that will facilitate the use of Arquer’s MCM5-ELISA test in a wide range of cancers. In April 2016, Stemcentrix acquired by AbbiVe along with its lead late stage biomarker rovalpituzumab tesirine (Rova-T), that helps to identify tumour cells. In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. FGFR3 developed at Institute Curie, it is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urine-based testing.

 


Global Cancer Biomarker Testing Market

MARKET SUMMARY
-
12.4%
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR– 12.4%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Cancer Biomarker Testing Market

  • Cancer market segmented based on type of cancer, application, bio molecule and end user.
  • Global Cancer Biomarker Testing Market Biomarker is any of body molecules that can be measured to assess the health. Molecules can be obtained from, body fluids, tissue or blood.
  • Biomarker testing is also known as genetic testing or molecular testing. Biomarker test is a group of tests that look for these molecular signs of health so that doctors can plan best care.
  • Cancer is referred as abnormal growth of the cells. Cancer biomarker is a process or substance that indicates the presence of cancer in the body. Genetic, epigenetic, glycemic, proteomic, and imaging biomarkers are used for cancer diagnosis, prognosis, and epidemiology.
  • These cancer biomarkers used as risk indicators for various types of cancer such as lung cancer, breast cancer and prostate cancer among the others. Key cancer biomarkers include SCC, CEA, NSE Cyfra 21, PSA (prostate cancer), TPA (Lung cancer), CA15-3, EGF R, Cytokeratin 4 (breast cancer) and BRCA ½.
Market Key Players
  • Thermo Fisher Scientific  (Affymetrix Inc.)
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Arquer Diagnostics Ltd.
  • Illumina, Inc.
  • Qiagen
  • Agilent Technologies
  • Merck & Co. Inc.
  • Becton Dickinson and Company
  • Hologic Inc.
Drivers and Restrains

Cancer Biomarker Testing Market

Companion diagnostics, tailored medications, and other disease diagnostics, such as disease risk assessment and drug research and development, all rely heavily on cancer biomarkers. One of the primary reasons likely to boost cancer biomarkers market growth during the projected period of 2021-2027 is the increased utilisation of biomarkers in disease diagnosis. The rising global prevalence of cancer is driving the need for early disease detection, which is propelling the market forward. According to the National Cancer Institute, 1,735,350 new cancer cases were reported in the United States in 2018. In addition, the World Cancer Research Fund International estimates that 18.0 million individuals worldwide were affected by cancer in 2018. Lung and breast cancers were the most prevalent cancers reported globally in 2018, accounting for 12.3 percent of all cases diagnosed. The increased incidence of cancer biomarkers in both developing and developed countries is expected to boost demand for cancer diagnostics and therapy. During the projection period of 2021-2027, these factors are expected to boost demand for these biomarkers. Despite the rising global incidence of cancer and the increasing number of patients requiring diagnostic tests, the lack of reimbursement regulations for biomarker tests in emerging and industrialised nations is one issue restricting global demand for these biomarkers. Another key stumbling block to the market’s expansion is the high cost of cancer diagnosis and treatment in developing countries. This is reducing the number of patients who are tested for biomarkers, and patients are increasingly preferring other low-cost detection tests.


North-America Got Significant Share

Cancer Biomarker Testing Market

Geographically global market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to be a major market for cancer biomarker test market owing to increase in research and development activities to diagnose and treating cancer and rise in prevalence of cancer. According to American Cancer Society (ACS), in 2017, it estimates 1,688,780 new cancer cases are diagnosed and 600,920 cancer deaths in the U.S. alone. Asia-Pacific cancer biomarker test market is expected to be fastest growing market due to increase in demand for the non-invasive techniques in diagnosis and prevention of cancer, high prevalence of cancer conditions in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015 to 2020) and forecast (2021 to 2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Cancer Biomarker Testing Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Thermo Fisher Scientific  (Affymetrix Inc.) (U.S.)
  • Abbott Laboratories (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AbbVie Inc. (U.S.)
  • Arquer Diagnostics Ltd. (U.K.)
  • Illumina, Inc. (U.S.)
  • Qiagen (Germany)
  • Agilent Technologies (U.S.)
  • Merck & Co. Inc. (U.S.)
  • Becton Dickinson and Company (U.S.)
  • Hologic Inc. (U.S.)

Description

Global Cancer Biomarker Testing Market was valued at USD 10.42 billion in 2020 and is anticipated to grow at USD 20.59 billion by 2027 recording a CAGR of 12.4% during the forecast period 2021-2027. The cancer biomarker test market is driven by rising prevalence of cancer worldwide. World Health Organization (WHO) stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2012. The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO’s funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market. The global market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2017, Foundation Medicine and Bristol-Myers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient’s response to cancer immunotherapy. Using Foundation Medicine’s foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in patients enrolled in clinical trials for Bristol-Myers Squibb (BMS) cancer drugs. For instance, in October 2016, Arquer Diagnostics Ltd. (Arquer), and University of Sunderland are collaborated to investigate noninvasive specimen preparation techniques that will facilitate the use of Arquer’s MCM5-ELISA test in a wide range of cancers. In April 2016, Stemcentrix acquired by AbbiVe along with its lead late stage biomarker rovalpituzumab tesirine (Rova-T), that helps to identify tumour cells. In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. FGFR3 developed at Institute Curie, it is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urine-based testing.

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX